Represented a major pharmaceutical company in Wood v. Abbott Laboratories, an indirect purchaser name brand prescription antitrust class action, which alleged that name brand pharmaceutical companies overcharged Michigan retail pharmacists and those overcharges were passed on to consumers and payors. The case was resolved in the defendants' favor after defendants defeated class certification by proving that the complexity and diversity of wholesale and retail pricing practices in the industry meant that plaintiffs' claims could not be established through common proofs.